"专利悬崖"正在引发投资人担忧。过去一年来，默沙东股价累计下跌超过三分之一。默沙东急需找到填补K药"巨大缺口"的重磅药物，而且可能不止需要一 个药物。 维罗纳制药开发的一种治疗慢性阻塞性肺病的吸入性药物恩塞芬汀（Ohtuvayre）已经获得美国FDA批准上市，该药物在2024年的销售额为4230万美元。投 行杰弗瑞（Jeffries）分析师预计，到2030年代中期，该药物的收入峰值将有望达到30亿至40亿美元。 根据研究公司Evaluate Pharma的数据，2027年至2028年间，预计将有年销售额超过1800亿美元的药物迎来专利到期，这一规模占全球药品市场约12%。包括 百时美施贵宝（BMS）和辉瑞等巨头公司都在努力应对畅销药物专利到期的困境。 近一年半来，医药市场大手笔的收购相比过去几年要少得多。2023年是生物医药大规模交易的顶峰之年，当年辉瑞斥资430亿美元收购肿瘤药公司Seagen， 安进斥资280亿美元收购自免药制造商Horizon Therapeutics。但此后的18个月，医药并购市场表现平静，鲜有超过百亿美元规模的收购。 当地时间7月9日，制药巨头默沙东宣布将以约100亿美元价格收购英国 ...

HPV感染是全球重要的公共卫生问题之一，在"加速消除宫颈癌全球战略"及"健康中国战略"全面推进的 时代背景下，HPV疫苗成为公共健康体系的重要支柱和重要防线。而高价次HPV疫苗可预防更多病毒亚 型，防护更全面，因而备受消费者追捧。 现如今，随着国产九价HPV疫苗进入公众视野，"HPV疫苗怎么选"再次成为热议焦点。相同价次下，如 何选择最优HPV疫苗考验着消费者的决策能力。 在HPV疫苗这个充满期待的领域里，默沙东凭借超高市场占有率，一直稳居HPV疫苗的领导地位。而在 目前上市的九价HPV疫苗中，默沙东的佳达修®9是唯一获批用于预防由7种高危型HPV(16、18、31、 33、45、52、58型)引起的宫颈癌的九价疫苗，且凭借男性适应证在中国的获批成为首个且目前唯一获 批、可适用于男性及女性接种的九价HPV疫苗。这也标志着中国正式进入了"男女共防HPV共创免疫预 防新时代"。 作为全球首个九价HPV疫苗的研发者，默沙东的故事或许能为我们提供另一种视角——一款疫苗的价 值，不仅在于价格标签，更在于其历经时间检验的守护能力。 百年积淀：从实验室到全球的"疫苗基因" 1891年，默沙东的前身在新泽西州成立时，或许未曾 ...

Core Viewpoint - The announcement of the pricing for the first domestically produced nine-valent HPV vaccine "Xinkening®9" by Wantai Biological Pharmacy, priced at 499 yuan per dose, represents a significant development in the HPV vaccine market in China, being approximately 40% cheaper than imported alternatives [1] Company Summary - Wantai Biological Pharmacy has launched "Xinkening®9", the first domestic nine-valent HPV vaccine in China and the second globally [1] - The vaccine is designed to prevent infections from seven high-risk HPV types (16, 18, 31, 33, 45, 52, 58) and two low-risk types (6, 11), along with related diseases [1] Industry Summary - The pricing strategy of "Xinkening®9" at 499 yuan per dose positions it competitively against imported nine-valent HPV vaccines, which are significantly more expensive [1] - This development may enhance access to HPV vaccination in China, potentially increasing vaccination rates and public health outcomes [1]

Core Viewpoint - The launch of China's first domestically produced nine-valent HPV vaccine "Xinkening®9" at a price of 499 yuan per dose significantly undercuts the imported vaccine priced at 1300 yuan, marking the end of the "high-price era" for HPV vaccines [1] Group 1: Product Pricing and Market Impact - The domestic nine-valent HPV vaccine is priced at approximately 40% of the imported vaccine's market standard price [1] - The competitive pricing is expected to enhance the willingness of eligible women to get vaccinated, contributing to the establishment of a national immunity barrier and accelerating the goal of cervical cancer elimination [1] - The pricing strategy is projected to benefit over 100 million women in China and positively impact global cervical cancer prevention efforts [1] Group 2: Company Initiatives and Global Expansion - After the approval of the nine-valent HPV vaccine, the company is actively advancing the national bidding and procurement process as per its established plan [1] - The company is also working diligently on the WHOPQ certification process for the nine-valent HPV vaccine, leveraging its international achievements with the two-valent HPV vaccine, which has gained market access in over 20 countries and is included in the immunization programs of 8 countries [1] - The company expresses confidence in accelerating the overseas access and expansion of the nine-valent HPV vaccine through its established global network [1]

Core Viewpoint - The launch of the domestic nine-valent HPV vaccine "Xinkening 9" by Wantai Biological Pharmacy is a significant advancement in the market, offering a cost-effective alternative to imported vaccines, priced at approximately 40% of the import cost [1][6]. Group 1: Vaccine Efficacy and Safety - "Xinkening 9" has demonstrated comparable immune response and safety to imported nine-valent HPV vaccines, as evidenced by head-to-head clinical trial results published in The Lancet Infectious Diseases [2]. - The vaccine effectively prevents persistent infections from seven high-risk HPV types associated with cervical cancer, establishing a protective barrier for women aged 18-45 [2]. Group 2: Market Impact and Accessibility - As the only approved HPV vaccine for ages 9-17 with a two-dose regimen, "Xinkening 9" is expected to significantly improve vaccination compliance and rates among young girls in China [3]. - The pricing strategy of "Xinkening 9" is anticipated to enhance the willingness of eligible women to receive the vaccine, contributing to the establishment of a national immunity barrier against cervical cancer [6]. Group 3: Research and Development Achievements - The development of "Xinkening 9" reflects over 18 years of collaborative research between Xiamen University and Wantai Biological, showcasing China's advancements in HPV vaccine technology [4]. - Wantai Biological has invested approximately 1 billion yuan in the research and development of the nine-valent HPV vaccine, highlighting the commitment to innovation in this field [5]. Group 4: Public Health Implications - The introduction of a more affordable HPV vaccine aligns with global and national strategies to accelerate the elimination of cervical cancer, with a significant portion of the target population in China yet to receive vaccination [2][6].

《每日经济新闻》记者注意到，每支499元的定价大幅拉低了九价HPV疫苗价格。 与此同时，国产HPV疫苗企业中，还有沃森生物（SZ300142）、康乐卫士（BJ 833575）、瑞科生物 （HK02179）等公司的产品正排队上市。这意味着，九价疫苗的价格竞争或许刚刚开始。 每经记者｜陈星 每经编辑｜文多 7月8日，首个国产九价HPV疫苗公布定价。 据万泰生物（SH603392）消息，该公司旗下的"馨可宁9"定价499元/支，定价约为进口九价HPV疫苗的 40%。 此前，默沙东旗下九价HPV疫苗先后通过扩龄、降低接种剂次、获批男性接种等方式尽可能地占领先发 优势。而万泰生物九价疫苗除了祭出价格优势外，在"出海"、男性接种等方面也试图发力。 万泰生物在8日发布的投资者关系活动记录中写道，公司正在全力推进九价HPV疫苗WHO PQ（世界卫 生组织预认证）认证进程，依托公司二价HPV疫苗已取得的国际化成果（已在海外获得20多个国家的市 场准入，并被纳入8个国家的免疫规划项目）和公司构建的全球化网络，万泰生物有信心将以更快的速 度推动九价HPV疫苗的海外准入及拓展。 二剂次接种费用约998元 7月8日，万泰生物公开旗下" ...

2020年，世界卫生组织正式提出"加速消除宫颈癌全球战略"，我国亦印发《加速消除宫颈癌行动计划 （2023-2030）》，并将"促进HPV疫苗接种"列为行动主要目标之一。截至目前，我国3亿9至45岁女性 中，未接种HPV疫苗的比例高达70%至80%。 根据不完全统计，厦门大学方面一共有包括院士在内的十多名疫苗科学家深入参与了研发项目。而万泰 生物则前后投入了约20名博士、150名硕士实现了产品的工程化。 资料显示，万泰生物成立于1991年，主营业务为体外诊断试剂、自动化检测设备、疫苗研发生产及销 售。公司的主要产品目前包括原料、质控品、诊断设备、免疫、生化、分子、疫苗在内的全产业链医防 融合产品，横跨七个不同的技术平台。该公司于2020年在上海证券交易所主板成功上市，其控股股东为 养生堂有限公司，实控人为农夫山泉创始人、董事长钟睒睒。 经过万泰生物和厦门大学长达18年的攻坚克难，馨可宁®9展现出了不输进口疫苗的试验数据。据2023 年7月刊发在《柳叶刀·感染病学》上的头对头临床试验结果表明，馨可宁®9与进口九价HPV疫苗具有 相似的免疫应答及安全性。此外，预防HPV持续感染是预防宫颈癌的第一道防线，已经被国际 ...

人民健康是社会主义现代化的重要标志。江西省始终把保障人民健康放在优先发展的战略位置，将"民 生事"当作"头等事"，将民生"问题清单"转化为"履职清单"，奋力打造新时代卫生健康"四区四高地"，着 力解决群众急难愁盼问题，努力补足"健康底色"、擦亮"幸福成色"，持续提升人民健康水平。 跑出普惠托育服务"加速度" 2022年，江西建立婴幼儿入托补贴制度，并将其列入省政府民生实事，对按当地政府普惠指导价招收3 岁以下婴幼儿的托育机构，根据普惠托育机构实际招收的托育人数和月数，按每托位每月200元给予补 助。持续加大婴幼儿入托补贴补助力度，2023年，将婴幼儿入托补贴补助标准提高100元，达到每托位 每月300元，为群众提供服务优质、价格普惠的婴幼儿照护服务。3年来，全省共发放入托补贴约2亿 元，补助托位19.32万个，切实减轻家庭经济负担，助力生育友好型社会建设，人口出生率连续多年位 居全国第一方阵。 织牢保护女性健康"安全网" 为保护和促进女性健康，江西积极响应世界卫生组织提出的"加速消除宫颈癌全球战略"，于2023年 将"为适龄女生免费接种HPV疫苗"工作列入省政府民生实事，发布了《宫颈癌防治口诀》，健全完善覆 ...

Core Viewpoint - Zhifei Biological plans to issue up to 6 billion yuan in corporate bonds to support investments in technological innovation, replace interest-bearing liabilities, and replenish working capital [1] Group 1: Financial Performance - In 2024, Zhifei Biological reported a significant decline in performance, with total revenue of 26.07 billion yuan, a year-on-year decrease of 50.7%, and a net profit attributable to shareholders of 2.02 billion yuan, down 75.0% [1] - The revenue from agency products, which has historically contributed over 70% to the company's performance, saw a drastic reduction, leading to the overall decline in revenue [1][2] - The company's cash flow turned negative in 2024, with an operating cash flow of -4.414 billion yuan, a decline of 149.6% compared to the previous year [3] Group 2: Product Performance - Revenue from Zhifei Biological's self-developed products increased by 14.9% to 1.18 billion yuan, while revenue from agency products fell by 52.5% to 24.67 billion yuan [2] - The core product, the HPV vaccine, experienced a significant drop in sales, with the issuance of four-valent HPV vaccines down by 95.5% and nine-valent HPV vaccines down by 14.8% [2] Group 3: Strategic Initiatives - The company aims to focus on "de-stocking, collecting payments, and reducing liabilities" as its core strategy for 2025 to mitigate operational risks [3] - The issuance of 6 billion yuan in corporate bonds is seen as a crucial step in reducing liabilities and addressing financial risks [3]

"陕西女首富"巨子生物范代娣与"山东女首富"华熙生物赵燕的激战正酣之际，中国医美圈又发生了一件 大事，连续四年蝉联"中国首富"的钟睒睒，盯上了"山西女首富"锦波生物杨霞的"胶原蛋白"。 锦波生物公告称，钟睒睒通过旗下两家企业养生堂、杭州久视，以最高34亿元的投资，成为了锦波生物 第二大股东。 两位首富的联姻，旋即引发轩然大波。尤其是卖水的钟睒睒，为何会主动出击、盯上重组胶原蛋白赛 道？锦波生物，到底有何吸引人之处？ 钟睒睒主动出击背后 近日，锦波生物发布了拟引入战投的公告，称向养生堂发行不超过717.57万股，拟募资20亿元。同时， 锦波生物实控人杨霞将其持有的575.33万股股份作价14.03亿元，协议转让给杭州久视。养生堂、杭州久 视背后的实控人均为钟睒睒。 从2021年以来，钟睒睒已连续四年蝉联中国内地首富王座，而支撑其首富王座的，则是农夫山泉、万泰 生物两家堪比"印钞机"的上市公司。 2020年4月，万泰生物以8.75元/股的发行价登陆上交所。很快，万泰生物股价涨至296.8元/股，涨幅超 30倍。2021年，万泰生物股价进一步攀升，市值更是突破千亿元。 同年9月，农夫山泉以21.50港元/股的价格登 ...